Ace Inhibitor - DOAJ

Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-AnalysisPlain-Language Summary

"Rationale and Object: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy to reduce proteinuria in primary and genetic focal segmental glomerulosclerosis patients following guidelines based on other proteinuria-related kidney diseases. " The effects of RAAS inhibitor therapy on kidney function in these patients were analyzed in this systematic review. The eight patients were rated RAAS inhibitor monotherapy, while the remainder were tested RAAS inhibitors in combination with other medications, mainly immunosuppressants. Patients undergoing RAAS inhibitor monotherapy showed a 36 percent proteinuria reduction and no change in creatinine clearance from baseline to the last published follow-up. The published results did not include reporting of the effects of RAAS inhibitor monotherapy on estimated glomerular filtration rate and end-stage kidney disease risks. Strong evidence to quantify the effects of RAAS inhibitor monotherapy on end-stage kidney disease and glomerular filtration rate was lacking.

Source link: https://doi.org/10.1016/j.xkme.2022.100457

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions